• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipDEA

Report: The Government Is About to Open Up Research on Marijuana

By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
Down Arrow Button Icon
By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
Down Arrow Button Icon
August 10, 2016, 11:37 PM ET
Federal Heights medical marijuana
FEDERAL HEIGHTS, CO - JULY 26: Medical marijuana products at Green Sativa on July 26, 2016, in Federal Heights, Colorado. In November 2014, Federal Heights residents voted to permit medical marijuana facilities within the city. Green Sativa opened in March, the first to do so. (Photo by Anya Semenoff/The Denver Post via Getty Images)Anya Semenoff/ Denver Post via Getty Images

The U.S. government will announce on Thursday that it will allow more research into marijuana but has rejected requests to relax the classification of the substance as a dangerous, highly addictive drug with no medical use, sources with direct knowledge of the matter said.

The decision is the Drug Enforcement Administration’s response to a 2011 petition by two former state governors who had urged federal agencies to re-classify marijuana as a drug with accepted medical uses, the two sources said on Wednesday. They requested anonymity because they were not authorized to discuss the matter publicly.

The DEA declined to comment. However earlier on Wednesday, the agency had sent emails, a copy of which was reviewed by Reuters, to parties that had expressed an interest in the matter, saying it would be making “important announcements regarding marijuana related topics” on Thursday.

See also: Here’s How You Can Watch the Pot Industry’s ‘Shark Tank’

The Food and Drug Administration did not respond immediately to requests for comment.

For decades, marijuana has been classified as a “Schedule I” drug with “no currently accepted medical use and a high potential for abuse,” on par with heroin. The government has repeatedly rejected appeals over the years to reclassify marijuana. Loosening that definition could encourage scientific study of a drug that is being used to treat diseases in several U.S. states despite little proof of its effectiveness.

 

Twenty-five states have sanctioned some forms of marijuana use for medical purposes. Four states – Alaska, Washington, Oregon, and Colorado – and the District of Columbia have gone even further, allowing its recreational use for adults.

California and eight other states have recreational or medical marijuana proposals headed for their 2016 ballots.

See also: Valeant Executives May Be Facing Criminal Prosecution

A drug can be reclassified through congressional legislation or a formal scheduling petition process that involves medical and scientific evaluation by the FDA and DEA.

The DEA only allows marijuana for federally sanctioned research to be cultivated at a garden at the University of Mississippi, an operation overseen by the National Institute on Drug Abuse.

Cannabis advocates have long argued that this arrangement, and the labeling of marijuana as among “the most dangerous drugs” under the Controlled Substances Act, has sharply limited the supply available for research.

The sources said the federal government would pave the way on Thursday for increased research, possibly with marijuana supplies from outside the University of Mississippi.

“This is a good day for science,” said Kevin Sabet, president of Smart Approaches to Marijuana, a group that opposes legalization. “This shows that the federal government is flexible on legitimate research but is nowhere near wanting to legalize marijuana.”

About the Authors
By Reuters
See full bioRight Arrow Button Icon
By Michelle Toh
See full bioRight Arrow Button Icon

Latest in Leadership

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
North America
'I meant what I said in Davos': Carney says he really is planning a Canada split with the U.S. along with 12 new trade deals
By Rob Gillies and The Associated PressJanuary 28, 2026
2 days ago
placeholder alt text
Politics
The American taxpayer spent nearly half a billion dollars deploying federal troops to U.S. cities in 2025, CBO finds
By Nick LichtenbergJanuary 28, 2026
2 days ago
placeholder alt text
C-Suite
Jeff Bezos capped his Amazon salary at $80,000: ‘How could I possibly need more incentive?’
By Sydney LakeJanuary 28, 2026
2 days ago
placeholder alt text
C-Suite
Fortune 500 CEOs are no longer giving employees an A for effort. Now they want proof of impact
By Claire ZillmanJanuary 28, 2026
2 days ago
placeholder alt text
Investing
Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted
By Eva RoytburgJanuary 29, 2026
24 hours ago
placeholder alt text
Personal Finance
Current price of silver as of Thursday, January 29, 2026
By Joseph HostetlerJanuary 29, 2026
24 hours ago

Latest in Leadership

AICollaboration
Are you a cyborg, a centaur, or a self-automator? Why businesses need the right kind of ‘humans in the loop’ in AI
By François Candelon, Katherine Kellogg, Hila Lifshitz and Steven RandazzoJanuary 30, 2026
3 hours ago
NewslettersCEO Daily
Inside Starbucks CEO Brian Niccol’s nascent turnaround plan—and why it’s working
By Phil WahbaJanuary 30, 2026
4 hours ago
InvestingIndonesia
Indonesia exchange CEO steps down as MSCI reform pressure mounts
By Prima Wirayani, Abhishek Vishnoi and BloombergJanuary 30, 2026
4 hours ago
A man works on two computers while a coworker looks on in the background.
AIGen Z
Gen Z believes using AI is making their colleagues dumb and lazy, but may paradoxically see it as key to their own promotion, Wharton says
By Sasha RogelbergJanuary 30, 2026
5 hours ago
Man with glasses smiling before a blue background.
InvestingInvestment
$14 trillion asset manager BlackRock unveils its newest weapon in Wall Street ‘alts’ talent war: profit sharing from private markets
By Amanda GerutJanuary 30, 2026
6 hours ago
C-SuiteFortune 500: Titans and Disruptors of Industry
Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19
By Eva RoytburgJanuary 29, 2026
13 hours ago